Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer (SYSUCC-001)
|ClinicalTrials.gov Identifier: NCT01112826|
Recruitment Status : Completed
First Posted : April 28, 2010
Last Update Posted : September 11, 2017
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: Capecitabine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||432 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase III Study of Adjuvant Capecitabine Metronomic Chemotherapy in Triple-negative Operable Breast Cancer|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||December 2016|
|Actual Study Completion Date :||December 2016|
Capecitabine 650 mg/m2 bid
capecitabine 650 mg/m2 twice every day for 1 year.
No Intervention: Standard treatment
Treatment according to National Comprehensive Cancer Network (NCCN) guideline.
- disease-free survival [ Time Frame: 36 months ]The final analysis are expected to occur 18 and 36 months after the end of recruitment.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01112826
|Sun Yat-sen University, Cancer Center|
|Guangzhou, Guangdong, China, 510060|
|Study Director:||Yuan Zhong-yu, MD||Sun Yat-sen University|